We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.

Advanced search
Date range (dd-mm-yyyy)

Avacta

ESMO 2026 data supports pre|CISION PDC targeting

Update | 29 October 2026

Avacta

£12.5m raise completed, runway extended into Q227

Lighthouse | 06 October 2026

Scancell

Atlantic crossing transforms outlook

Update | 06 October 2026

Avacta

H126: pre|CISION pipeline progress prompts fundraise

Lighthouse | 30 September 2026

Avacta

Encouraging first data from AVA6103 Phase Ia study

Update | 16 September 2026

HUTCHMED

First ATTC deal: GSK $110m upfront for KRAS/EGFR

Lighthouse | 04 September 2026

Oxford BioDynamics

£9m raise gives management time to enact strategy

Lighthouse | 27 August 2026

HUTCHMED

SAFFRON data positions savo combo competitively

Lighthouse | 18 August 2026

HUTCHMED

H126: China recovery and Fruzaqla drive sales growth

Lighthouse | 31 July 2026

Scancell

Strategic transactions to unlock longer-term value

Lighthouse | 23 July 2026
1 2 3 4 5 6 7 8 9 10 >
507 results found.